Mar­ket is­sues prey on po­ten­tial bounce­back for an­tibi­otics, says a new re­port — here's how to fix it

In the realm of drug R&D, the dra­mat­ic col­lapse of the an­tibi­otics space — es­pe­cial­ly in light of the steady growth of an­tibi­ot­ic re­sis­tance — has been ob­vi­ous for years now. And ac­cord­ing to an­a­lysts at in­dus­try group BIO, it’s not been an is­sue with the drug-to-FDA suc­cess rate, where de­vel­op­ers in the field have seen a rel­a­tive­ly high rate of suc­cess.

The in­dus­try group re­leased its of­fi­cial re­port on an­tibi­otics this morn­ing, not­ing new trends about the pipeline for an­tibi­otics and the con­tin­u­ing ex­o­dus of bio­phar­ma and in­vestors, all point­ing to mar­ket is­sues at play. And the an­a­lysts have a few ur­gent sug­ges­tions on how to cure the field of what ails it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER